NovaBay Pharmaceuticals to Hold First Quarter 2019 Conference Call on May 9, 2019
30 April 2019 - 8:50PM
Business Wire
Management to discuss new partner pharmacy
program and expanded access to in-office direct channel
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® for the domestic eye care market, announces that it will
report first quarter 2019 financial results after market close on
Thursday, May 9, 2019 and will hold an investment community
conference call that day.
In addition to discussing financial results during the call,
management will provide updates on recent initiatives to increase
sales while decreasing costs. The sales initiatives entail improved
patient accessibility to Avenova through an expanded partner
pharmacy program and increased outreach efforts to eye care
specialists to sell Avenova directly to their patients through its
in-office direct channel. Management will also provide an update on
previously announced cost-containment measures to align expenses
with the recent strategic shift in its commercialization
strategy.
DATE: Thursday, May 9 TIME: 4:30 p.m. ET /
1:30 p.m. PT DIAL IN: 800-608-8202 from within the U.S.
702-495-1913 from outside the U.S. Enter conference identification
number 8495204
The live call also will be available at
http://novabay.com/investors/events. A replay of the call will be
available beginning two hours after its completion through 11:59
p.m. Pacific time May 17, 2019, by dialing 855-859-2056 from within
the U.S. or 404-537-3406 from outside the U.S. and entering the
conference identification number 8495204. The call will also be
archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Socialize and Stay informed on
NovaBay’s progress:Like us
on FacebookFollow us on TwitterConnect with
NovaBay on LinkedInJoin us on Google+Visit
NovaBay’s Website
Avenova Purchasing
InformationFor NovaBay Avenova purchasing
information:Please call 800-890-0329 or
email sales@avenova.com.www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190430005264/en/
NovaBay ContactJustin
HallInterim President and Chief Executive
Officer510-899-8800jhall@novabay.com
Investor ContactLHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024